Showing posts with label dose. Show all posts
Showing posts with label dose. Show all posts
Monday, September 06, 2010
abstract: Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac follow-up?
"PLD is cardiac safe for long-term treatment of metastatic solid tumors. Its maximal cumulative dose remains undefined. "
add your opinions
cardiac
,
dose
,
doxil
,
heart
,
longterm followup
,
pegylated liposomal doxorubicin
,
safety
Monday, March 08, 2010
Choice of Starting Dose for Molecularly Targeted Agents Evaluated in First-in-Human Phase I Cancer Clinical Trials
Purpose: One tenth of the lethal dose to 10% of mice is one of the conventional parameters used to derive a safe starting dose in phase I trials of cytotoxic agents. There is no consensus on which preclinical models and parameters should define the starting dose for molecularly targeted agents.
Friday, March 05, 2010
Accurate accumulation of dose for improved understanding of radiation effects in normal tissue
Int J Radiat Oncol Biol Phys. 2010 Mar
Jaffray DA, Lindsay PE, Brock KK, Deasy JO, Tomé WA.
Princess Margaret Hospital, Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada. david.jaffray@rmp.uhn.on.ca
Abstract:
The actual distribution of radiation dose accumulated in normal tissues over the complete course of radiation therapy is, in general, poorly quantified.
Differences in the patient anatomy between planning and treatment can occur gradually (e.g., tumor regression, resolution of edema) or relatively rapidly (e.g., bladder filling, breathing motion) and these undermine the accuracy of the planned dose distribution. Current efforts to maximize the therapeutic ratio require models that relate the true accumulated dose to clinical outcome. The needed accuracy can only be achieved through the development of robust methods that track the accumulation of dose within the various tissues in the body. Specific needs include the development of segmentation methods, tissue-mapping algorithms, uncertainty estimation, optimal schedules for image-based monitoring, and the development of informatics tools to support subsequent analysis. These developments will not only improve radiation outcomes modeling but will address the technical demands of the adaptive radiotherapy paradigm.
The next 5 years need to see academia and industry bring these tools into the hands of the clinician and the clinical scientist.
Wednesday, February 10, 2010
Finding the Right Dose for Cancer Therapeutics—Can We Do Better? — Clinical Cancer Research
Note: very short abstract as below, but good points (in the absence of the full paper)
Abstract:
"Unlike other diseases, dose-selection for cancer therapeutics is often based on the maximum-tolerated dose in phase 1 studies involving relatively few patients. In this issue of Clinical Cancer Research, Jain and colleagues provide evidence that lower doses may be as effective as maximum-tolerated doses in the treatment of cancer patients."
add your opinions
clinical trials
,
dose
,
phase 1
Subscribe to:
Posts
(
Atom
)